Why Jim Cramer Likes Regeneron (REGN) Stock Over Sanofi (SNY)

NEW YORK (TheStreet) -- TheStreet's Jim Cramer talks about the breakout news of Regeneron  (REGN) and its partner Sanofi  (SNY) , which teamed up to create a cholesterol drug called alirocumab that would be used with the statin class of cholesterol drugs to decrease the hard-to-reduce cholesterol levels. 

Cramer says this is great news for the approximately 12 million people who are allergic to the statin class. He thinks this is a multi-billion dollar drug for Regeneron and the company is finally breaking out. Cramer thinks this makes all sorts of sense because the drug cuts heart rate failure risk and stroke risk.

Cramer thinks Renegeron is a better way to play this news than Sanofi.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

REGN Chart REGN data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round